Immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ Human Papillomavirus (HPV) 580299 vaccine in healthy Chinese female subjects. - Trial 2012-003025-25

Name: Clinical Trial 2012-003025-25
Creator: GlaxoSmithKline Biologicals
Keywords: Healthy volunteers, clinical trial

Access comprehensive clinical trial information for 2012-003025-25 through Pure Global AI's free database. This phase not specified trial is sponsored by GlaxoSmithKline Biologicals and is currently status unknown. The study focuses on Healthy volunteers.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database

840K+ Trials

2012-003025-25

Trial Details

EU Clinical Trials Register • 2012-003025-25

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ Human Papillomavirus (HPV) 580299 vaccine in healthy Chinese female subjects.

Study Focus

Disease/Condition

Healthy volunteers

Sponsor & Location

Primary Sponsor

GlaxoSmithKline Biologicals

Timeline & Enrollment

Phase

N/A

Start Date

N/A

End Date

N/A

Primary Outcome

Evaluation of immune responses to components of the study vaccine: Antibody GMTs (by ELISA) against HPV-16/18 antigens.

ICD-10 Classifications

Healthy person accompanying sick person

Routine general health check-up of armed forces

Routine general health check-up of sports teams

Routine general health check-up of inhabitants of institutions

Data Source

Registry

EU Clinical Trials Register

Trial ID

2012-003025-25

Type

Non-Device Trial